Familial Chylomicronemia Syndrome Clinical Trial
Official title:
Olezarsen (ISIS 678354) Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
The purpose of the Expanded Access Program is to provide pre-approval access of olezarsen to eligible patients with Familial Chylomicronemia Syndrome (FCS).
The Expanded Access Program (EAP) is intended to provide pre-approval access to olezarsen for eligible patients with FCS who have limited or no available treatment options. This program is open in the United States and operates under the individual patient (also referred to as single patient) IND expanded access route in which the patient's treating physician serves as the sponsor. Expanded access requests must be from the patient's treating physicians and submitted according to the instructions at https://www.ionispharma.com/patients/expanded-access-policy/ ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04223908 -
InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia
|
||
| Active, not recruiting |
NCT05130450 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
|
Phase 3 | |
| Completed |
NCT04568434 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
|
Phase 3 | |
| Completed |
NCT03912181 -
Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes
|
||
| Not yet recruiting |
NCT05902598 -
A Phase 3 Study of VSA001 in Chinese Adults With Familial Chylomicronemia Syndrome
|
Phase 3 | |
| Active, not recruiting |
NCT05185843 -
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
|
Phase 3 | |
| Completed |
NCT02658175 -
The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
|
Phase 3 | |
| Completed |
NCT03360747 -
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
|
Phase 2 | |
| Completed |
NCT02211209 -
The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
|
Phase 3 |